In the modified intention-to-treat analysis ( patients receiving six or more doses of study drugs ) , 28-day all-cause mortality was 7.3 % with ulinastatin ( 4 deaths ) versus 20.3 % ( 12 deaths ) with placebo ( p = 0.045 ) .